Big Technologies Secures Major Contracts in Lithuania and US, Launches FCC-Approved AlcoBreath

Big Technologies wins in Lithuania, Latvia and the US – with ARR tailwinds into 2026

Big Technologies has posted a neat pre-Christmas trading update. The headlines: fresh contract wins in Lithuania, Latvia and Pierce County (Washington state) – subject to final contract – plus a signed deal in Prince Edward Island, Canada. There is also a new US partnership with Recovery Monitoring Solutions (RMS) and an FCC-approved alcohol monitoring device called AlcoBreath.

Management says these awards boost confidence that trading is in line with market expectations for 2025, with a fuller update due at the end of January 2026.

Contract wins: useful diversification and 2026 ARR

All newly announced contracts are expected to contribute to ARR (annual recurring revenue – the ongoing subscription revenue from customers) during 2026 as deployments go live. That matters because it should reduce customer concentration and strengthen revenue visibility.

The standout is Lithuania. It carries an initial ARR of £0.6 million expected to land in 2026, with scope to grow to a total contract value of up to approximately €6 million over a three-year term. The company has not disclosed sizes for the other wins.

Contract/Award	Status	Expected Contribution	Timing
Lithuania	Awarded (subject to final contract)	Initial ARR of £0.6m; potential TCV up to c. €6m over 3 years	ARR expected to materialise in 2026
Latvia	Awarded (subject to final contract)	Not disclosed	ARR expected in 2026
Pierce County, Washington (USA)	Awarded (subject to final contract)	Not disclosed	ARR expected in 2026
Prince Edward Island, Canada	Contract signed	Not disclosed	ARR expected in 2026

Why these wins matter

• Recurring model – The group’s SaaS-like (subscription) approach means new contracts typically bring multi-year, high-visibility revenue.
• Geographic spread – Adding the Baltics and expanding in North America reduces reliance on any single customer or country.
• Pipeline for 2026 – The uplift is mostly in 2026, so think of this as backlog-building rather than an immediate FY2025 step-up.

US commercial push: partnership with RMS

Big Technologies has struck a strategic partnership with Recovery Monitoring Solutions (RMS) in the US to supply alcohol monitoring and GPS products to RMS’s client base. RMS brings a 32-year track record and a distribution footprint across US justice and compliance programmes.

This looks like a leveraged go-to-market model: Buddi brings product, RMS brings channels and relationships. Commercial terms are not disclosed, but if executed well this could accelerate US penetration without Big shouldering the full cost of direct sales expansion.

AlcoBreath gets FCC approval – opening the US alcohol monitoring market

AlcoBreath is a new handheld device that combines breath alcohol detection, real-time GPS tracking, and facial recognition. It has received FCC approval in the US. The FCC (Federal Communications Commission) certifies electronic devices for radio compliance – a necessary step for sale in the States.

Management sees a significant market for compliance-based alcohol monitoring, particularly in the US. Pairing FCC-approved hardware with the RMS partnership is strategically tidy: you have the product and a channel to sell it. Pricing, deployment pace and margin profile are not disclosed.

Guidance, consensus and trading momentum

The company says it has seen rapid progress in the second half of 2025 following organisational and operational investments, and it remains confident of meeting full-year guidance. The balance sheet is described as strong, with operational cash flow supporting ongoing investment – no figures disclosed.

Metric (FY2025)	Range	Consensus
Revenue	£48.5m – £49.5m	£49.1m
Adjusted EBITDA	£23.7m – £24.5m	£24.1m

Adjusted EBITDA is earnings before interest, tax, depreciation and amortisation, adjusted for certain items. Hitting the midpoints here would signal healthy profitability for a subscription-heavy model.

My take: steady execution, broader footprint, and a new product leg

This readout is encouraging. The contract flow should diversify and enlarge ARR through 2026, the RMS tie-up provides a US growth vector, and AlcoBreath adds a new adjacent product category with regulatory clearance already banked. It aligns with management’s comments about market tailwinds in electronic monitoring and a clear growth strategy.

It is also sensible expectation management. Most of the revenue impact lands in 2026, not this year, and management is signalling “in line” with current forecasts for 2025 rather than pushing guidance up today. That is disciplined rather than flashy.

Positives

• Contract momentum across multiple geographies, with Lithuania the clearest near-term ARR contribution.
• Reduced customer concentration as new programmes go live.
• US channel leverage via RMS, well matched to the AlcoBreath launch.
• Confidence in meeting FY2025 revenue of around £49.1m and adjusted EBITDA of around £24.1m (consensus).

Watch-outs

• Contract finalisation – Lithuania, Latvia and Pierce County are still subject to final contract. Timelines can slip.
• Ramp timing – Management guides that ARR will materialise over 2026; the quarterly phasing is not disclosed.
• Commercial terms – No detail on pricing, margins or unit economics for the new deals or the RMS partnership.
• Regulatory scope – FCC approval covers the US. Certifications for other regions are not mentioned.

What to watch next

• End-January 2026 trading update – Confirmation of FY2025 delivery versus the consensus ranges.
• Contract signings and go-live dates – Converting the awarded programmes into deployed, billing ARR.
• Early traction for AlcoBreath in the US – Orders via RMS and any initial customer case studies.

Bottom line

Big Technologies is quietly doing the right things: winning across new jurisdictions, adding a fresh product with US approval, and partnering to scale in the States. The financial uplift is a 2026 story, but today’s update improves visibility and reduces concentration risk. If execution stays tight, the combination of ARR growth and strong margins should remain a compelling mix.